Dublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Age-related Macular Degeneration Market by Type (Dry Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration), Treatment Modality (Pharmaceuticals, Surgical Interventions), Delivery Method, Healthcare Setting, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.
The Age-related Macular Degeneration Market grew from USD 10.45 billion in 2023 to USD 11.10 billion in 2024. It is expected to continue growing at a CAGR of 6.67%, reaching USD 16.43 billion by 2030.
Recent years have witnessed dramatic changes in the landscape of age-related macular degeneration management. A combination of scientific breakthroughs and technological advancements is driving a paradigm shift that redefines therapeutic approaches and market potential. Ongoing developments in diagnostic imaging and molecular biology have paved the way for early detection strategies and more nuanced patient profiling. This evolution has led to earlier intervention protocols, significantly altering the treatment trajectory for patients affected by both dry and wet forms of AMD.
Parallel to clinical innovations, there has been a substantial transition in patient care models and healthcare infrastructure. The traditional reactive approach to retinal diseases has given way to proactive, data-driven methodologies. A burgeoning emphasis on precision medicine ensures that treatments are increasingly tailored to individual patients based on genetic, demographic, and lifestyle factors, which in turn reshapes the competitive dynamics across pharmaceutical and surgical intervention spheres. Furthermore, partnerships between academic institutions, research organizations, and industry players are fostering cross-disciplinary collaborations that catalyze breakthrough discoveries.
These market shifts also underscore the importance of adaptive strategies for stakeholders, as companies recalibrate their portfolios to incorporate emerging therapies and integrated treatment modalities. A comprehensive understanding of these transformative shifts provides continuous opportunities for investors and care providers to enhance patient outcomes while maximizing market share.
Key Regional Trends and Emerging Opportunities
The analysis of regional trends highlights a diverse and evolving market landscape marked by unique regional characteristics and growth prospects. In North America, robust healthcare infrastructure coupled with a high prevalence of chronic conditions has streamlined early diagnosis and intervention for AMD. Continuous investments in research and development have ensured that the Americas remains at the forefront of innovative clinical trials and breakthrough therapies.
Exploring the landscape across Europe, the Middle East, and Africa reveals a region where regulatory reforms and increased awareness have boosted market expansion. Intensive cross-border collaborations and public-private partnerships are catalyzing clinical advancements, while regional healthcare policies are adapting to support earlier diagnosis and more effective treatment modalities. Emerging economies within these regions are increasingly recognizing the importance of investing in modern ophthalmological care, thereby creating additional opportunities for market growth.
The Asia-Pacific region presents another dynamic and rapidly expanding market segment. Economic growth, coupled with improved healthcare delivery systems and heightened consumer awareness, is driving a surge in demand for both conventional and advanced treatment options. Ongoing investments in healthcare infrastructure and localized research initiatives are further positioning the region as a key contributor to global market dynamics. As stakeholders leverage these regional insights, a comprehensive understanding of localized challenges and opportunities continues to inform strategic planning and resource allocation decisions.
Leading Companies Shaping the Future of AMD Management
The dynamic landscape of age-related macular degeneration is reinforced by the active involvement of numerous established and emerging companies that are setting new benchmarks in vision care. The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include:
- AbbVie Inc.
- Adverum Biotechnologies, Inc.
- Alkeus Pharmaceuticals, Inc.
- Allegro Ophthalmics, LLC
- Amgen Inc.
- Annexon, Inc.
- Apellis Pharmaceuticals, Inc.
- AsclepiX Therapeutics
- Astellas Pharma Inc.
- Bausch Health Companies Inc.
- Bayer AG
- Biocon Ltd
- Biogen Inc.
- Clearside Biomedical, Inc.
- EyePoint Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- Formycon AG
- Grifols, SA
- Ionis Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- Kodiak Sciences Inc.
- Lineage Cell Therapeutics, Inc.
- Lupin Limited
- Merck & Co. Inc.
- Nicox SA
- Novartis AG
- PanOptica, Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sandoz Group AG
- Sun Pharmaceutical Industries, Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Strategic Recommendations for Industry Leaders
Industry leaders need to insulate themselves against market volatility while simultaneously embracing innovation to drive forward progress in the AMD space. Strategic recommendations suggest prioritizing robust clinical research to validate the emerging therapies and provide clear evidence of their efficacy through rigorous clinical trials. Investing in cutting-edge diagnostic modalities and fostering closer collaborations with academic institutions can provide valuable insights into the evolving biological pathways that underpin AMD.
Leaders should also align their operational strategies with evolving regulatory frameworks that govern patient care and treatment innovations. Emphasizing agile supply chain management and ensuring the integrity of distribution channels can help companies balance risk while capitalizing on emerging market opportunities. Embracing digital technologies to streamline patient engagement and monitoring processes is equally crucial in today's technology-driven ecosystem.
Diversifying portfolios across both pharmaceutical and surgical interventions, based on evolving treatment protocols, can mitigate risks associated with market saturation and competitive overlap. Industry stakeholders are advised to assess the merits of multi-channel distribution strategies that take into account variations in regional regulatory landscapes and consumer preferences. Integrating real-world evidence analytics into decision-making processes can further enhance market responsiveness and optimize resource allocation.
In today's competitive environment, it is imperative that industry decision-makers adopt a holistic, data-driven approach. This means leveraging structured market segmentation insights and integrating them with robust forecasting models, while encouraging collaborative engagements across both public and private sectors. Such strategic imperatives are designed to fortify competitive positioning and ensure sustained growth in the long term.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 185 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $11.1 Billion |
| Forecasted Market Value (USD) by 2030 | $16.43 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
Key Topics Covered
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing number of geriatric population across the world
5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD
5.1.2. Restraints
5.1.2.1. Potential risk of drug recalls associated with AMD
5.1.3. Opportunities
5.1.3.1. Significant government policies & funding for AMD
5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
5.1.4. Challenges
5.1.4.1. Stringent regulatory environment and complex approval of new treatments
5.2. Market Segmentation Analysis
5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments
5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration
5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration
5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments
5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care
5.3. Porter's Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
5.5. Client Customization
5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country
6. Age-related Macular Degeneration Market, by Type
6.1. Introduction
6.2. Dry Age-Related Macular Degeneration
6.3. Wet Age-Related Macular Degeneration
7. Age-related Macular Degeneration Market, by Treatment Modality
7.1. Introduction
7.2. Pharmaceuticals
7.2.1. Anti-inflammatory Drugs
7.2.2. Anti-VEGF Agents
7.2.3. Antioxidants & Supplements
7.2.4. Gene Therapy Drugs
7.3. Surgical Interventions
7.3.1. Laser Therapy
7.3.2. Macular Translocation Surgery
7.3.3. Photodynamic Therapy
7.3.4. Vitrectomy
8. Age-related Macular Degeneration Market, by Delivery Method
8.1. Introduction
8.2. Injectable
8.3. Intravitreal implants
8.4. Oral
9. Age-related Macular Degeneration Market, by Healthcare Setting
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
9.4. Ophthalmology Clinics
10. Age-related Macular Degeneration Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Americas Age-related Macular Degeneration Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Age-related Macular Degeneration Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Age-related Macular Degeneration Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis
14.2. FPNV Positioning Matrix
14.3. Competitive Scenario Analysis
14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision
14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes
14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina
14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients
14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment
14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment
14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results
14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics' AVD-104 targeting age-related macular degeneration
14.3.9. Retinal Degeneration Fund's major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life
14.4. Strategy Analysis & Recommendations
14.4.1. F. Hoffmann-La Roche Ltd.
14.4.2. Novartis AG
14.4.3. Bayer AG
14.4.4. Astellas Pharma Inc.
For more information about this report visit https://www.researchandmarkets.com/r/me5euw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
